0001415889-24-009019.txt : 20240322
0001415889-24-009019.hdr.sgml : 20240322
20240322194623
ACCESSION NUMBER: 0001415889-24-009019
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240320
FILED AS OF DATE: 20240322
DATE AS OF CHANGE: 20240322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ballal Rahul D.
CENTRAL INDEX KEY: 0001805097
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 24776663
MAIL ADDRESS:
STREET 1: 116 HUNTINGTON AVENUE
STREET 2: 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
4
1
form4-03222024_110316.xml
X0508
4
2024-03-20
0001672619
Enliven Therapeutics, Inc.
ELVN
0001805097
Ballal Rahul D.
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
true
false
false
false
1
Common Stock
2024-03-20
4
M
0
13278
5.52
A
35619
D
Common Stock
2024-03-20
4
S
0
13278
19.1642
D
22341
D
Stock Option (right to buy)
5.52
2024-03-20
4
M
0
13278
0
D
2032-01-27
Common Stock
13278
19571
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings.
This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.
/s/ Ben Hohl, by power of attorney
2024-03-22